Cantharidin topical Pregnancy and Breastfeeding Warnings

Brand names: Ycanth

Medically reviewed by Drugs.com. Last updated on Dec 8, 2023.

Cantharidin topical Pregnancy Warnings

Safety has not been established during pregnancy

US FDA pregnancy category: Not assigned

Risk summary: Topical administration of this drug results in low systemic absorption and maternal use is unlikely to cause fetal exposure.

Comments:
-No data available on the use of this drug in pregnant women to inform a drug-related risk.

Animal reproduction studies were not conducted with this drug. There are no controlled data in human pregnancy.

US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help healthcare providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.

See references

Cantharidin topical Breastfeeding Warnings

Caution is recommended.

Excreted into human milk: Unknown
Excreted into animal milk: Unknown

Comments:
-Breastfeeding is not expected to result in the exposure of the child to this drug due to its low systemic absorption following topical administration.
-This solution should not be applied to areas at increased risk for potential ingestion or ocular exposure by breastfed children.
-The developmental and health benefits of breastfeeding and the mother's clinical need for this drug should be considered before administration.

See references

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer